OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX 427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmacology studies. More information is available at http://www.oncogenex.ca.
This press release contains forward-looking statements, including
statements concerning clinical trial results, future partnering activities
and the economic benefits from developing OGX-011. These statements are
based on management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause actual
results to differ materially from those described in the forward-looking
statements. All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. For example,
statements regarding the timing and anticipated results of clinical trials
and development efforts, future partnering activities and e
|SOURCE OncoGenex Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved